> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# ‘Procedural’ Observations in FDA Lupin Inspection
- URL: https://www.fdaweb.com/procedural-observations-in-fda-lupin-inspection/
- Published: 2018-12-07T12:00:00.000Z
- Updated: 2026-09-15T00:49:23.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142984

India’s Lupin Pharmaceuticals says FDA 11/26-12/4 inspections at the firm’s Mandideep location found “largely procedural” observations. Mandideep houses the company’s cardiovascular “Pril” active pharmaceutical ingredient (API) facilities, cephalosprorin API facilities, and cephalosporin solid oral dosage form facility. The company says the “Pril” API facilities closed with four inspection observations, the cephalosporin API facilities with 10 observations, and the cephalosporin solid dose facilities with eight observations.

“The company is confident of addressing them satisfactorily,” it says.